tag payments 
Pharmaceutical Technology
MAY 1, 2023
CTH-004 is developed by genetically altering patient T cells for inserting a chimeric antigen receptor (CAR) to target a marker (TAG-72) on ovarian cancer cells and delete genes which are involved in T cell function suppression. The company stated that the agreement structure includes a licence fee, milestone payments, as well as royalties.
The Pharma Data
AUGUST 18, 2020
The $475 million price tag on the deal will be made by BMS in near-term upfront payments, and Dragonfly will have access to further milestone payments contingent on regulatory and commercial successes of drugs under the partnership, as well as up to 24% royalties on net sales worldwide. .
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Rethinking Clinical Trials
OCTOBER 18, 2023
It is often that you have to take the raw values and harmonize to a particular insurance type (source of payment typology). Tags #pctGR, @Collaboratory1 The post Grand Rounds October 13, 2023: Incorporating Social Determinants of Health Into PCORnet (Keith Marsolo, PhD) appeared first on Rethinking Clinical Trials.
Rethinking Clinical Trials
DECEMBER 6, 2022
It was a labor of love; the site payment was low; we asked friends to be sites in the trial. It’s almost always harder in my experience. Sites have a lot of trials that are competing. One pays more than another. We did what we could to make the entry criteria as easy as possible. pctGR, @Collaboratory1.
XTalks
JUNE 28, 2023
million price tag of Elevidys, a one-time gene therapy. Instead of a treatment outcome-based payment approach that has been adopted by other gene therapies to help with costs, Sarepta is working on “some innovative concepts” with payers, he said. In a media call, Sarepta CEO Douglas Ingram revealed the $3.2
pharmaphorum
APRIL 14, 2022
million price tag. ” bluebird is proposing that bet-cel will be paid for in five equal payments for patients who achieve and maintain free of transfusions, a goal achieved by 89% of patients in its clinical trials after a median of 42 months’ follow-up.
Drug Discovery World
JANUARY 30, 2024
She said: “Payment options will be devised to absorb the costs. One Developing value-based payment models that consider long-term benefits could improve access. Other Challenges: Limited insurance coverage: Many insurance companies are hesitant to cover CGTs due to their high price tags and limited long-term data.
Expert insights. Personalized for you.
130 
Let's personalize your content